|
1. FDA pauses Regenxbio trial again after spine masses found in 5 patients Full story
2. FDA approves new first-line treatments for 3 cancers Full story
3. It’s not the most advanced robots winning in ASCs — it’s the simplest here.
4. Lilly, Novo Nordisk’s fight against GLP-1 copycats Full story
5. 6 new FDA approved drugs to know Full story
6. Treat EMS data as an enterprise strategy, not just an ED handoff. Learn why here.
7. Thyroid drug recalled nationwide over superpotency risk Full story
8. 10 drug categories with the most active shortages Full story
Becker’s Learning Opportunities
9. Symptoms worsen and patients disengage between oncology visits. See how to give patients more support — without straining teams — here.
10. AI results in the contact center have been uneven. Tampa General and UChicago Medicine show what’s working + what’s not in this webinar.
11. Separating purchasing and reimbursement data quietly compounds pharmacy’s financial risk. See the fix here.
12. Becker’s late-August webinar lineup: patient safety, referral intake, AI trust and supply chain data. See the sessions here.
Apply to attend complimentary as a guest reviewer here! Opportunity exclusive to those directly employed by a provider organization.
|
.png)
